RCKT250117C15000
- 0.05
- 0.000.00%
Rocket Pharmaceuticals Newsroom
J.P. Morgan Maintains Rocket Pharmaceuticals(RCKT.US) With Buy Rating, Cuts Target Price to $48
Wedbush Maintains Rocket Pharmaceuticals(RCKT.US) With Buy Rating, Maintains Target Price $32
BofA Securities Maintains Rocket Pharmaceuticals(RCKT.US) With Buy Rating, Maintains Target Price $37
Wedbush Maintains Rocket Pharmaceuticals(RCKT.US) With Buy Rating, Cuts Target Price to $32
Promising Pipeline and Strategic Developments Propel Rocket Pharmaceuticals to 'Buy' Rating
Jefferies Initiates Rocket Pharmaceuticals(RCKT.US) With Buy Rating, Announces Target Price $29
Rocket Pharmaceuticals Price Target Announced at $29.00/Share by Jefferies
Rocket Pharmaceuticals Analyst Ratings
Jefferies Initiates Rocket Pharmaceuticals(RCKT.US) With Buy Rating, Announces Target Price $29
Leerink Partners Maintains Rocket Pharmaceuticals(RCKT.US) With Buy Rating, Cuts Target Price to $40
Leerink Partners Adjusts Rocket Pharmaceuticals Price Target to $40 From $44, Maintains Outperform Rating
A Quick Look at Today's Ratings for Rocket Pharmaceuticals(RCKT.US), With a Forecast Between $37 to $55
Rocket Pharmaceuticals Price Target Maintained With a $39.00/Share by Canaccord Genuity
Rocket Pharmaceuticals Receives Buy Rating Due to Promising RP-A501 Data and FDA Alignment for Danon Disease Treatment
Rocket Pharmaceuticals Is Maintained at Outperform by Leerink Partners
Cantor Fitzgerald Reiterates Overweight on Rocket Pharmaceuticals, Maintains $65 Price Target
A Quick Look at Today's Ratings for Rocket Pharmaceuticals(RCKT.US), With a Forecast Between $37 to $52
Rocket Pharmaceuticals Price Target Maintained With a $52.00/Share by Needham
Rocket Pharmaceuticals' RP-A501 Shows Promising Long-Term Efficacy and Safety in Danon Disease Treatment: Buy Rating Affirmed
Rocket Pharmaceuticals Analyst Ratings